Back to search results
NCT07638982

Axatilimab + CAR-T for High-Risk Lymphoma

Not Yet Recruiting
PHASE1Ages 8+InterventionalTreatment
Northside Hospital, Inc.
~29 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Axatilimab

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Determine the recommended Phase 2 dose (RP2D) of axatilimab
Measured over 1 year
+1 more outcome measured

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
High-grade B-cell Lymphoma (HGBCL)
High-Grade B-Cell Lymphoma, Nos
PMBCL
Follicular Grade 3 Lymphoma

Explore related trials

Diffuse Large B-Cell LymphomaFollicular LymphomaHigh Grade B-Cell LymphomaHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

NCT07638982

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Northside Hospital

    Atlanta, Georgiastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Joseph Maakaron, MD
[email protected]
404-255-1930
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Histologically confirmed large B-cell lymphoma
Presence of one or more high-risk features
Eligible to receive CAR-T according to the FDA label
Measurable disease by CT or PET
Adequate organ function unless related to lymphoma involvement:
Pulse oximetry ≥ 92% on room air
Ejection Fraction ≥ 40%
ALT/AST \< 5x ULN
Bilirubin \< 3 x ULN
Calculated or measured creatinine Clearance ≥ 30 mL/min

Exclusion

KPS \<60
Second malignancy with a high metastatic potential within 3 years
Active CNS involvement. Treated CNS disease is allowed
Active HBV or HCV infection.
Active uncontrolled infections
Known HIV positive status
Allogeneic transplant within 100 days of enrollment
Active acute or chronic graft versus host disease
History of acute or chronic pancreatitis
History of myositis

What this trial measures

  • Determine the recommended Phase 2 dose (RP2D) of axatilimab1 year

    Determine the recommended Phase 2 dose (RP2D) of axatilimab in combination with CAR T cell therapy by following a fast-track dose escalation design and assessing adverse events, using the CTCAE Version 6, related to axatilimab

  • Estimate 1 year progression-free survival1 year

    Estimate 1 year progression-free survival by assessing disease status at 1 year following CAR T infusion